Globucel

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Primary immunodeficiency syndromes
• Secondary immunodeficiencies
• Chronic inflammatory demyelinating polyneuropathy
• Idiopathic thrombocytopenic purpura
• Kawasaki disease
• Certain viral infections

Dosage

Children: Refer to specific clinical guidelines or the BNF for Children for detailed dosing information, as it varies based on the condition being treated.

Adults: Refer to specific clinical guidelines or the BNF for detailed dosing information, as it varies based on the condition being treated.

Mechanism of action

Immunoglobulins exert their action by binding to specific antigens on pathogens, marking them for destruction by immune cells. They can neutralize toxins and viruses, facilitate opsonization (enhancing phagocytosis), and activate the complement system, leading to lysis of pathogens.

Pharmacodynamics

The pharmacodynamic effects of immunoglobulins include modulation of the immune response, providing passive immunity, and potential anti-inflammatory effects. They can help restore antibody levels in patients with deficiencies and may also have roles in regulating immune responses in autoimmune conditions.

Pharmacokinetics

Immunoglobulins are typically administered intravenously or subcutaneously. After administration, they enter the systemic circulation and are distributed throughout the body. The half-life of immunoglobulins varies but is generally around 21 to 30 days. They are metabolized by the reticuloendothelial system and excreted primarily through the kidneys.

Contra-indications

• Hypersensitivity to immunoglobulin products
• Severe hyperprolinemia
• Selective IgA deficiency (in some cases)

Adverse effects

• Headache
• Fever
• Chills
• Fatigue
• Nausea
• Vomiting
• Rash
• Anaphylaxis (rare)
• Thromboembolic events (rare)

Interactions

• Live attenuated vaccines may be less effective if administered concurrently with immunoglobulin
• Anticoagulants may have altered effects in patients receiving immunoglobulin

Precautions

• Monitor for signs of anaphylaxis during administration
• Use with caution in patients with renal insufficiency
• Consider risk of thromboembolic events in patients with a history of cardiovascular disease

Pregnancy

Immunoglobulins are generally considered safe during pregnancy and are often used to provide passive immunity to the fetus.

Breast-feeding

Immunoglobulins are safe to use during breastfeeding, and they can provide passive immunity to the infant through breast milk.

Storage

Store at 2 to 8 degrees Celsius, do not freeze. Protect from light and use within the specified time after opening.

Formulations

• Intravenous immunoglobulin (IVIG)
• Subcutaneous immunoglobulin (SCIG)
• Intramuscular immunoglobulin (IMIG)

Indications

• Primary immunodeficiency syndromes
• Secondary immunodeficiency
• Immunomodulation in certain autoimmune disorders
• Prevention of infections in patients undergoing immunosuppressive therapy

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations in pediatric patients, as it varies based on age, weight, and clinical condition.

Adults: Refer to the BNF for specific dosing recommendations for adults, as it varies based on clinical indications and patient circumstances.

Mechanism of action

Normal immunoglobulin works by providing a broad spectrum of antibodies that neutralize pathogens and enhance the immune response. These antibodies bind to pathogens, facilitating their removal by immune cells and providing immediate passive immunity against infections.

Pharmacodynamics

The pharmacodynamic effects of normal immunoglobulin include the neutralization of toxins and pathogens, opsonization, and enhancement of phagocytosis. It modulates immune responses and provides immediate humoral immunity, particularly in individuals with inadequate antibody production.

Pharmacokinetics

Normal immunoglobulin is administered intravenously or subcutaneously. After administration, it is distributed throughout the body, with a half-life of approximately 21 to 30 days. It is metabolized by the reticuloendothelial system, and the rate of clearance can vary based on individual patient factors and the presence of underlying conditions.

Interactions

• normal immunoglobulin + monoclonal antibodies: Severe (affects effects)
• normal immunoglobulin + dinutuximab: Severe (affects effects)
• normal immunoglobulin + live vaccines, measles, mumps and rubella vaccine, live, rotavirus vaccine, typhoid vaccine, oral, varicella-zoster vaccine: Unknown (decreases efficacy)
• normal immunoglobulin + bacillus Calmette-Guérin vaccine: Unknown (decreases efficacy)
• normal immunoglobulin + herpes-zoster vaccine: Unknown (decreases efficacy)
• normal immunoglobulin + live: Unknown (decreases efficacy)
• normal immunoglobulin + influenza vaccine, live: Unknown (decreases efficacy)

Pregnancy

Consult relevant guidelines for use in pregnancy.

Breast-feeding

Consult relevant guidelines for use during breastfeeding.

Storage

Store at 2-8°C. Do not freeze.